BIND extends deal with Pfizer to develop and commercialize multiple Accurins
BIND is focused on developing targeted and programmable therapeutics called Accurins. The deal was originally established in April 2013 and the timeline for Pfizer to exercise its option
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.